Biogen (BIIB) Scheduled to Post Quarterly Earnings on Wednesday

Biogen (NASDAQ:BIIB) will issue its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of $3.99 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Biogen Price Performance

Shares of Biogen stock opened at $248.63 on Tuesday. The firm has a fifty day simple moving average of $256.85 and a 200-day simple moving average of $277.06. The company has a current ratio of 3.27, a quick ratio of 2.86 and a debt-to-equity ratio of 0.43. Biogen has a 1-year low of $233.76 and a 1-year high of $319.76. The stock has a market capitalization of $36.01 billion, a price-to-earnings ratio of 13.53, a PEG ratio of 2.59 and a beta of 0.10.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 431 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $269.43, for a total value of $116,124.33. Following the completion of the sale, the insider now owns 3,354 shares of the company’s stock, valued at approximately $903,668.22. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Biogen

Several large investors have recently made changes to their positions in BIIB. Norges Bank acquired a new stake in shares of Biogen in the 4th quarter valued at approximately $362,129,000. Price T Rowe Associates Inc. MD lifted its holdings in Biogen by 49.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,088,356 shares of the biotechnology company’s stock valued at $580,627,000 after purchasing an additional 691,843 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Biogen by 113.6% during the 1st quarter. AQR Capital Management LLC now owns 422,486 shares of the biotechnology company’s stock valued at $117,012,000 after purchasing an additional 224,668 shares during the last quarter. State Street Corp lifted its holdings in Biogen by 2.8% during the 1st quarter. State Street Corp now owns 7,208,906 shares of the biotechnology company’s stock valued at $1,518,196,000 after purchasing an additional 197,400 shares during the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in Biogen by 365.9% during the 1st quarter. Balyasny Asset Management L.P. now owns 239,395 shares of the biotechnology company’s stock valued at $66,559,000 after purchasing an additional 188,012 shares during the last quarter. Institutional investors and hedge funds own 85.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. StockNews.com began coverage on shares of Biogen in a research report on Thursday, October 5th. They set a “buy” rating on the stock. Truist Financial reduced their price target on shares of Biogen to $340.00 and set a “buy” rating on the stock in a research report on Tuesday, August 8th. Wells Fargo & Company reduced their price target on shares of Biogen from $350.00 to $343.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. Wedbush cut their target price on shares of Biogen from $270.00 to $266.00 and set a “neutral” rating on the stock in a research report on Thursday, October 26th. Finally, Morgan Stanley cut their target price on shares of Biogen from $381.00 to $361.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $328.21.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.